Gene-surrogate | Flexible two-phase design options | Expected Phase One counts | Power# | Cost* | |||||
---|---|---|---|---|---|---|---|---|---|
Spec | Sens | n0 | n1 | ρ0† | ρ1‡ | N0 | N1 | ||
70% | 80% | 700 | 500 | 90% | 80% | 5163 | 1525 | 81% | 1534 |
70% | 90% | 600 | 500 | 90% | 80% | 4412 | 1472 | 80% | 1394 |
80% | 60% | 700 | 300 | 90% | 90% | 7721 | 1491 | 80% | 1461 |
80% | 70% | 600 | 300 | 90% | 80% | 6585 | 1259 | 80% | 1292 |
80% | 80% | 500 | 300 | 90% | 80% | 5461 | 1200 | 80% | 1133 |
80% | 90% | 400 | 400 | 90% | 80% | 4348 | 1528 | 81% | 1094 |
90% | 60% | 400 | 400 | 70% | 50% | 6667 | 1683 | 81% | 1217 |
90% | 70% | 500 | 300 | 50% | 50% | 5896 | 1169 | 80% | 1153 |
90% | 80% | 500 | 300 | 40% | 60% | 4673 | 1307 | 80% | 1099 |
90% | 90% | 500 | 300 | 40% | 50% | 4630 | 1019 | 82% | 1082 |